Eurofins Scientific SE Stock OTC Markets
Stocks
ERRFY
US29873U1060
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 12.04B 13.76B 11.1B 10.29B 19.53B 1,306B 19.84B 133B 51.76B 645B 51.67B 50.55B 2,228B | P/E 2026 * |
23.9x | P/E 2027 * | 18.4x |
|---|---|---|---|---|---|
| Enterprise Value | 15.49B 17.7B 14.27B 13.23B 25.11B 1,680B 25.52B 171B 66.55B 829B 66.44B 65B 2,865B | EV / Sales 2026 * |
2.04x | EV / Sales 2027 * | 1.87x |
| Free-Float |
58.35% | Yield 2026 * |
1.12% | Yield 2027 * | 1.3% |
Last Transcript: Eurofins Scientific SE
| 1 day | +19.90% |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 1986-12-31 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 2014-12-31 |
Christian Wurst
PRN | Corporate Officer/Principal | 53 | 2019-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 1986-12-31 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 2014-12-31 |
Valérie Hanote
BRD | Director/Board Member | 60 | 1989-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +19.90% | -17.31% | - | - | 13.71B | |
| -1.03% | +5.24% | +2.94% | +9.41% | 50.25B | |
| +0.25% | +1.70% | +419.39% | +621.71% | 40.39B | |
| -0.16% | +8.42% | +28.20% | +63.00% | 34.4B | |
| +1.10% | +7.77% | +28.18% | -3.96% | 34.38B | |
| +1.31% | -0.56% | +5.12% | +33.90% | 26.32B | |
| -0.35% | +0.09% | - | - | 16.64B | |
| -3.33% | +3.15% | +71.30% | +131.94% | 16.14B | |
| +3.79% | +8.88% | +106.63% | +106.63% | 13.75B | |
| -1.30% | -2.87% | +14.32% | -28.64% | 13.09B | |
| Average | +2.02% | +4.35% | +84.51% | +116.75% | 27.26B | |
| Weighted average by Cap. | +1.06% | +4.91% | +96.03% | +138.72% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.6B 8.68B 7B 6.49B 12.32B 824B 12.52B 83.98B 32.66B 407B 32.6B 31.9B 1,406B | 8.07B 9.23B 7.44B 6.9B 13.09B 876B 13.3B 89.23B 34.7B 432B 34.64B 33.89B 1,494B |
| Net income | 517M 590M 476M 441M 838M 56.04B 851M 5.71B 2.22B 27.65B 2.22B 2.17B 95.59B | 676M 773M 623M 578M 1.1B 73.33B 1.11B 7.47B 2.91B 36.19B 2.9B 2.84B 125B |
| Net Debt | 3.44B 3.93B 3.17B 2.94B 5.58B 373B 5.67B 38.04B 14.79B 184B 14.77B 14.45B 637B | 3.08B 3.52B 2.84B 2.63B 5B 335B 5.08B 34.09B 13.26B 165B 13.23B 12.95B 571B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
